Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed ...